Transthyretin Amyloidosis Treatment Market Report Scope & Overview:
The transthyretin amyloidosis treatment market size was valued at USD 7.81 billion in 2024 and is expected to reach USD 17.80 billion by 2032, growing at a CAGR of 14.64% over the forecast period of 2025-2032.
The transthyretin amyloidosis treatment market is experiencing strong growth as a result of increasing rates of diagnosis, the development of targeted therapies, and heightened awareness of hereditary and wild-type ATTR. Innovative treatments, such as RNA interference drugs and TTR stabilizers, are transforming therapy. Increased research efforts, approval of drugs by regulatory bodies, and favorable healthcare policies also continue to fuel growth in the market. For Instance, in November 2024, the FDA approved Alnylam Pharmaceuticals' subcutaneous RNA interference therapy, vutrisiran, marketed as Amvuttra, to treat cardiomyopathy with wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM). The therapy is indicated for administration in adult patients. The evolution towards earlier diagnosis and treatment via a customized approach will fuel the expansion in the upcoming forecast period.
The U.S. transthyretin amyloidosis treatment market size was valued at USD 3.11 billion in 2024 and is expected to reach USD 6.92 billion by 2032, growing at a CAGR of 14.27% over the forecast period of 2025-2032.
The U.S. dominates the North American transthyretin amyloidosis treatment market. This dominance is fueled by the developed healthcare infrastructure, early uptake of novel therapies, and the strong presence of major pharmaceutical players with expertise in genetic and orphan diseases.
Drivers:
Advancements in Treatment Options are Driving the Transthyretin Amyloidosis Treatment Market
The approval of new therapies, especially gene-silencing therapies, such as patisiran and vutrisiran, has transformed the transthyretin amyloidosis treatment market growth. These treatments operate by lowering the production of transthyretin protein, which causes amyloid deposits in organs, such as the heart and nerves. With these innovative treatments, patients now have access to more effective and targeted treatments. In contrast to conventional therapies, these treatments promise to stop or even reverse the disease process and bringing dramatic improvements in patient outcomes. The availability of such technologies has driven the market, as these therapies bring hope to patients who were once left with few choices.
For instance, according to NCBI, recent developments in nuclear cardiac imaging by technetium pyrophosphate scans have made it possible to diagnose ATTR-CM without requiring a cardiac biopsy. Consequently, more and more patients are now being screened and diagnosed with ATTR-CM. Thus, increasing numbers of patients are being screened and diagnosed with ATTR-CM. In parallel, survival has also increased, boosting its prevalence. Consequently, 5,000 to 7,000 new cases are diagnosed every year in the U.S.
Increasing Incidence of ATTR is Propelling the Transthyretin Amyloidosis Treatment Market
With the aging population globally, the incidence of wild-type transthyretin amyloidosis (ATTR), especially among elderly individuals, has been rising. Wild-type ATTR is distinguished by amyloid deposits in the nervous system and heart, causing serious conditions, such as peripheral neuropathy and heart failure. This increase in the number of cases, along with greater awareness and improved diagnostic techniques, has driven demand for therapies. Hereditary ATTR, which can be transmitted genetically and affect people at a younger age, is also driving the increased demand for therapies. As the identification of ATTR cases widens, patients are being diagnosed and treated earlier, propelling additional growth in the ATTR amyloidosis treatment market trends.
For instance, according to Orphanet, the global frequency of wild-type ATTR amyloidosis (ATTRwt amyloidosis) has been estimated to be around 1 in 5,800 individuals. Autopsy findings have shown fibrillar transthyretin deposits in the hearts of approximately 25% of older adults. Recent evidence has also studied the prevalence of this condition in heart failure and preserved ejection fraction patients, where the prevalence rate can be as high as 13%. Wild-type ATTR amyloidosis is also more frequently seen in males.
Restraints:
Regulatory Challenges are Restraining the Transthyretin Amyloidosis Treatment Market Analysis
The process of getting regulatory approval for new therapies in orphan diseases, such as transthyretin amyloidosis (ATTR) may be quite intricate and lengthy. As the disease is rare, there might not be many patients available for conducting clinical trials, which may result in insufficient data to fulfill the requirements of regulatory bodies. Consequently, firms can find it difficult to demonstrate the safety and efficacy of their treatments to regulatory bodies, such as the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).
By Therapy
In 2024, the targeted therapy segment dominated the transthyretin amyloidosis treatment market share with 87.14% due to the pervasive use of approved therapies including Pfizer's Vyndaqel (tafamidis), Alnylam's Onpattro (patisiran), and Amvuttra (vutrisiran). The therapies target the root cause of the disease by stabilizing or silencing the transthyretin protein, which improves patient outcomes and retards disease progression. The effectiveness and proven clinical advantages of these treatments have established them as the first choice among medical practitioners, thus enabling the segment to dominate the market.
The pipeline therapy market is anticipated to experience the fastest growth over the forecast period. This growth is supported by the ongoing drug development and clinical research, with new therapies, such as BridgeBio's acoramidis and Ionis Pharmaceuticals' eplontersen, launched during the period. These investigational drugs have been designed to provide enhanced efficacy while limiting side effects, further meeting the hereditary and wild-type transthyretin amyloidosis unmet medical needs. With growing investment in novel therapies and hopes for better patient outcomes in the future, the pipeline therapy segment growth in the future is expected to be stimulated by these factors.
By Type
In 2024, the ATTR with polyneuropathy (ATTR-PN) segment dominated the transthyretin amyloidosis treatment market with 78.25% market share. The growth is driven by the high incidence of hereditary transthyretin amyloidosis with polyneuropathy symptoms, which has resulted in earlier diagnosis and treatment. The presence of approved treatments, such as patisiran (Onpattro), vutrisiran (Amvuttra), and eplontersen (Wainua), has further established this segment as the market leader. These treatments have been effective in managing neurological symptoms, thereby improving patients' quality of life and encouraging their use on a large scale.
The ATTR with cardiomyopathy (ATTR-CM) segment is predicted to experience the fastest growth during the forecast period. Growth is driven by increasing awareness of the cardiac manifestation of transthyretin amyloidosis and improved diagnostic techniques, which lead to earlier diagnosis. The introduction of new therapies, such as acoramidis (Attruby) and the broadened indication of vutrisiran in ATTR-CM, creates an opportunity for the treatments. These trends, combined with an increasingly aging population at risk of cardiac diseases, are set to drive the rapid growth of the ATTR-CM segment during the forecast period.
By Disease
In 2024, the wild-type amyloidosis segment dominated the transthyretin amyloidosis treatment market with 54.08% share, as it is more prevalent among the aging population. This type of amyloidosis, previously underdiagnosed in many instances, has been more recognized due to improved diagnostic methods and greater awareness among medical professionals. The population trend of an aging population has further added to the increasing incidence of wild-type amyloidosis globally, thus fueling the need for effective treatments, resulting in the growth of wild-type ATTR amyloidosis treatment.
The hereditary transthyretin amyloidosis (hATTR) segment is anticipated to witness the fastest growth during the forecast period with a CAGR of 14.73%. This growth is driven by greater genetic testing, resulting in earlier and more precise diagnoses of familial cases. The approval and development of novel therapies, including gene-silencing drugs, such as patisiran and vutrisiran, have broadened the treatment paradigm for hATTR. Also, growing promotion programs and government initiatives toward the commercialization of orphan drugs has stimulated investment and research in the sector, thus fueling the growth of the segment.
By Distribution Channel
The hospital pharmacies segment led the transthyretin amyloidosis treatment market in 2024, with a revenue share of approximately 52.31% as transthyretin amyloidosis therapies are complex and may need to be administered intravenously while closely monitored. These complex therapies are best suited to hospital pharmacies for proper storage, preparation, and administration. They also perform an essential function in patient education and support for adherence, allowing for the smooth integration of treatments into overall care plans.
The online pharmacies segment is expected to register the fastest growth rate over the forecast period, with an approximate compound annual growth rate (CAGR) of 14.76%. The reason behind the growth is enhanced patient preference toward home delivery convenience and remote accessibility to medications. Online pharmacies provide competitive prices and an increased treatment scope, including coverage for underserved or rural populations. Issues with ensuring genuine medication and handling regulatory environments remain on top priority for growth of this segment.
North America dominated the transthyretin amyloidosis treatment market with 46.21% market share in 2024, owing to its established healthcare infrastructure, greater awareness of the disease, and the presence of dominant pharmaceutical and biotechnology firms. Early availability of cutting-edge therapeutics and favorable regulatory backing by agencies, such as the FDA, and heavy investments in research related to rare diseases, further enhance the leadership of the region. Furthermore, high diagnosis rates, along with higher levels of clinical trial activity and reimbursement support for new therapies, are continuing to drive regional market growth.
Asia Pacific is the fastest-growing region in the transthyretin amyloidosis treatment market analysis, with 15.68% CAGR over the forecast period. This increasing growth is driven by improving healthcare infrastructure, growing healthcare spending, increasing awareness regarding rare genetic disorders, and a growing patient population. China, Japan, and India are witnessing increasing clinical trial participation and quicker regulatory approval of innovative treatments, and the region is highly promising for pharmaceutical companies willing to extend their presence globally.
Europe has a high market share in the transthyretin amyloidosis treatment market because of increased awareness, early diagnosis initiatives, and the availability of well-developed healthcare infrastructure. Germany, the UK, and France are at the forefront in terms of treatment adoption. Germany leads in the European transthyretin amyloidosis treatment market due to the presence of a strong healthcare infrastructure, early embrace of new therapies, and dominance of the region by major pharmaceutical firms. The nation's enthusiasm for development, coupled with favorable regulatory policies, has supported the distribution and adoption of sophisticated treatments for transthyretin amyloidosis. Germany's focus on early diagnosis and all-encompassing patient care further helps it reign supreme in this niche market segment.
Latin America and the Middle East & Africa (MEA) are witnessing slow growth in the transthyretin amyloidosis treatment market. In Latin America, delayed diagnosis, lack of easy access to specialty treatment centers, and the expensive nature of emerging therapies such as RNA interference drugs are the drivers for the slow market growth. Similarly, in the MEA region, tight regulatory procedures and the lack of availability of advanced diagnostic equipment impede fast growth. Nevertheless, continuous efforts to develop healthcare infrastructure and raise disease awareness are likely to underpin incremental market growth in these markets.
Alnylam Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma, Prothena Corporation plc, Akcea Therapeutics, Eidos Therapeutics, SOM Biotech, AstraZeneca plc, Alexion Pharmaceuticals, and other players are the major players competing in the market.
March 2025 – Alnylam Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved AMVUTTRA (vutrisiran), the first RNA interference (RNAi) therapy demonstrated to lower cardiovascular death, hospitalizations, and urgent heart failure visits in adults with the diagnosis of ATTR amyloidosis with cardiomyopathy (ATTR-CM).
February 2024 – BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company with a focus on genetic diseases and cancers, reported that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) filed by the company for acoramidis, an investigational medicine under development to treat ATTR cardiomyopathy (ATTR-CM).
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 7.81 Billion |
| Market Size by 2032 | USD 17.80 Billion |
| CAGR | CAGR of 14.64% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Therapy (Targeted Therapy, Supportive Therapy, Pipeline Therapy) • By Type (ATTR with Polyneuropathy (ATTR-PN), ATTR with Cardiomyopathy (ATTR-CM)) • By Disease (Hereditary Transthyretin Amyloidosis, Wild Type Amyloidosis) • By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail Pharmacies, Online Pharmacies) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Thermo Fisher Scientific, Agilent Technologies, Shimadzu Corporation, Alnylam Pharmaceuticals, Pfizer Inc., Ionis Pharmaceuticals, BridgeBio Pharma, Prothena Corporation plc, Akcea Therapeutics, Eidos Therapeutics, SOM Biotech, AstraZeneca plc, Alexion Pharmaceuticals, and other players. |
Ans: The Transthyretin Amyloidosis Treatment Market is expected to grow at a CAGR of 14.64% from 2025 to 2032.
Ans: The Transthyretin Amyloidosis Treatment Market was USD 7.81 billion in 2024 and is expected to reach USD 17.80 billion by 2032.
Ans: Increasing Incidence of ATTR propelling the Transthyretin Amyloidosis Treatment Market Trends.
Ans: The “Targeted Therapy” segment dominated the Transthyretin Amyloidosis Treatment Market.
Ans: North America dominated the Transthyretin Amyloidosis Treatment Market in 2024.
Table Of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Prescription Trends (2024), by Region
5.3 Healthcare Spending, by Region (Government, Commercial, Private, Out-of-Pocket) (2024)
5.4 Market Growth and Forecast (2024-2032)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Transthyretin Amyloidosis Treatment Market Segmentation By Therapy
7.1 Chapter Overview
7.2 Targeted Therapy
7.2.1 Targeted Therapy Market Trends Analysis (2020-2032)
7.2.2 Targeted Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Supportive Therapy
7.3.1 Supportive Therapy Market Trends Analysis (2020-2032)
7.3.2 Supportive Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Pipeline Therapy
7.4.1 Pipeline Therapy Market Trends Analysis (2020-2032)
7.4.2 Pipeline Therapy Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Transthyretin Amyloidosis Treatment Market Segmentation By Type
8.1 Chapter Overview
8.2 ATTR with Polyneuropathy (ATTR-PN)
8.2.1 ATTR with Polyneuropathy (ATTR-PN) Market Trends Analysis (2020-2032)
8.2.2 ATTR with Polyneuropathy (ATTR-PN) Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 ATTR with Cardiomyopathy (ATTR-CM)
8.3.1 ATTR with Cardiomyopathy (ATTR-CM) Market Trends Analysis (2020-2032)
8.3.2 ATTR with Cardiomyopathy (ATTR-CM) Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Transthyretin Amyloidosis Treatment Market Segmentation By Disease
9.1 Chapter Overview
9.2 Hereditary Transthyretin Amyloidosis
9.2.1 Hereditary Transthyretin Amyloidosis Market Trends Analysis (2020-2032)
9.2.2 Hereditary Transthyretin Amyloidosis Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Wild Type Amyloidosis
9.3.1 Wild Type Amyloidosis Market Trends Analysis (2020-2032)
9.3.2 Wild Type Amyloidosis Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Transthyretin Amyloidosis Treatment Market Segmentation By Distribution Channel
10.1 Chapter Overview
10.2 Hospital Pharmacies
10.2.1 Hospital Pharmacies Market Trends Analysis (2020-2032)
10.2.2 Hospital Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Specialty Pharmacies
10.3.1 Specialty Pharmacies Market Trend Analysis (2020-2032)
10.3.2 Specialty Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Retail Pharmacies
10.4.1 Retail Pharmacies Market Trends Analysis (2020-2032)
10.4.2 Retail Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
10.5 Online Pharmacies
10.5.1 Online Pharmacies Market Trends Analysis (2020-2032)
10.5.2 Online Pharmacies Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.2.3 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.4 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.5 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.6 North America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.7.2 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.7.3 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.7.4 USA Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.8.2 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.8.3 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.8.4 Canada Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.2.9.2 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.2.9.3 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.2.9.4 Mexico Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe Mobile Payment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.3.3 Europe Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.4 Europe Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.5 Europe Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.6 Europe Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.7.2 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.7.3 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.7.4 Germany Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.8 France
11.3.8.1 France Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.8.2 France Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.8.3 France Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.8.4 France Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.9.2 UK Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.9.3 UK Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.9.4 UK Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyTransthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.10.2 Italy Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.10.3 Italy Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.10.4 Italy Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.11.2 Spain Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.11.3 Spain Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.11.4 Spain Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.12.2 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.12.3 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.12.4 Poland Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.13.2 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.13.3 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.13.4 Turkey Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.3.14.2 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.3.14.3 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.3.14.4 Rest of Europe Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.4.3 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.4 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.5 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.6 Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.7 China
11.4.7.1 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.7.2 China Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.7.3 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.7.4 China Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.8 India
11.4.8.1 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.8.2 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.8.3 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.8.4 India Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.9.2 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.9.3 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.9.4 Japan Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.10.2 South Korea Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.10.3 South Korea Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.10.4 South Korea Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.11.2 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.11.3 Singapore Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.11.4 Singapore Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.12.2 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.12.3 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.12.4 Australia Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.5.3 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.4 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.5 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.6 Middle East and Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.7.2 UAE Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.7.3 UAE Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.7.4 UAE Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.8.2 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.8.3 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.8.4 Saudi Arabia Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.1.9 Qatar
11.5.9.1 Qatar Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.9.2 Qatar Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.9.3 Qatar Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.1.9.4 Qatar Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.10.2 South Africa Mobile Payment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.5.10.3 South Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.10.4 South Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Payment Type (2020-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa Mobile Payment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Country (2020-2032) (USD Billion)
11.6.3 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.4 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.5 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.6 Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.7.2 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.7.3 Brazil Mobile Payment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.7.4 Brazil Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.8.2 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.8.3 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.8.4 Argentina Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Therapy (2020-2032) (USD Billion)
11.6.9.2 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Type (2020-2032) (USD Billion)
11.6.9.3 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Disease (2020-2032) (USD Billion)
11.6.9.4 Rest of Latin America Transthyretin Amyloidosis Treatment Market Estimates and Forecasts by Distribution Channel (2020-2032) (USD Billion)
12. Company Profiles
12.1 Alnylam Pharmaceuticals
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Pfizer Inc.,
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Ionis Pharmaceuticals
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 BridgeBio Pharma.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Prothena Corporation plc.
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Akcea Therapeutics
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Eidos Therapeutics
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 SOM Biotech
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 AstraZeneca plc.
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Alexion Pharmaceuticals
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Therapy
By Type
By Disease
By Distribution Channel
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/enquiry/6932
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/enquiry/6932
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
The Ambulatory Surgical Centers Market Size was valued at USD 124.87 billion in 2023 and is expected to reach USD 201.91 billion by 2031, and grow at a CAGR of 6.19% over the forecast period 2024-2031.
Companion Animal Arthritis Market was valued at USD 66.8 billion in 2023 and is expected to reach USD 125.58 billion by 2032, growing at a CAGR of 7.28% over the forecast period of 2024-2032.
The Laboratory Information Management System Market size to grow from USD 2.29 billion in 2023 to USD 4.61 billion by 2032, with a CAGR of 8.12%.
The GLP-1 Receptor Agonist Market size was USD 43.79 billion in 2023 and is projected to grow to USD 193.56 billion by 2032, with a CAGR of 17.61%.
The Cell And Gene Therapy Clinical Trials Market Size was valued at USD 9.48 billion in 2023 and is expected to reach USD 32.96 billion by 2032 and grow at a CAGR of 14.87% over the forecast period 2024-2032.
The Breast Cancer Liquid Biopsy Market was valued at USD 1.13 billion in 2023 and is expected to reach USD 2.37 billion by 2032, growing at a CAGR of 8.61% over the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2025 All Rights Reserved by SNS Insider Pvt Ltd
